Siponimod for Secondary Progressive Multiple Sclerosis (920)

Warning

exp date isn't null, but text field is

Abstract

Siponimod (Mayzent®) is accepted for use within NHS Scotland for the treatment of adult
patients with secondary progressive multiple sclerosis (SPMS) with active disease
evidenced by relapses (in the past 1 year) and / or imaging features of inflammatory
activity. This will be defined as new T2 lesions / contrasting enhancement / enlarging T2
lesion on MRI scan (at least one lesion within 1 year).

In a randomised, double-blind, placebo-controlled phase III study, siponimod was
associated with a reduction in disability progression confirmed after 3 months in patients with SPMS. Siponimod reduced the risk of 6-month confirmed disability progression by 26% compared to placebo.

Resources

Use the button below to access this resource item.

Access this resource

Tags

Acute / All Inpatient
All Primary Care

Last reviewed: 28 April 2021

Next review: 09 June 2024

Author(s): Pushkar Shah

Author Email(s): [email protected], [email protected]

Co-Author(s): Lesley Murray

Approved By: Medicines Utilisation Subcommittee of ADTC

Document Id: 920